VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of view.

Hematopoiesis Inflammation Myelodysplastic syndrome UBA1 VEXAS

Journal

Best practice & research. Clinical rheumatology
ISSN: 1532-1770
Titre abrégé: Best Pract Res Clin Rheumatol
Pays: Netherlands
ID NLM: 101121149

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 29 03 2023
revised: 29 06 2023
accepted: 24 07 2023
pubmed: 1 9 2023
medline: 1 9 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

The recently discovered VEXAS syndrome is caused by the clonal expansion of hematopoietic stem or progenitor cells with acquired mutations in UBA1 gene, which encodes for a key enzyme of the ubiquitylation proteasome system. As a result, a shorter cytoplasmic isoform of UBA1 is transcribed, which is non-functional. The disease is characterized by non-specific and highly heterogeneous inflammatory manifestations and macrocytic anemia. VEXAS syndrome is a unique acquired hematological monogenic disease with unexpected association with hematological neoplasms. Despite its hematopoetic origin, patients with VEXAS syndrome usually present with multi-systemicinflammatory disease and are treated by physicians from many different specialties (rheumatologists, dermatologists, hematologistis, etc.). Furthermore, manifestations of VEXAS may fulfill criteria for existing diseases: relapsing polychondritis, giant cell arteritis, polyarteritis nodosa, and myelodysplastic syndrome. The goal of this review is to depict VEXAS syndrome from a hematologic point of view regarding its consequences on hematopoiesis and the current strategies on therapeutic interventions.

Identifiants

pubmed: 37652853
pii: S1521-6942(23)00047-5
doi: 10.1016/j.berh.2023.101861
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101861

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Maël Heiblig (M)

Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'hématologie clinique, Lyon, France; Université Claude Bernard Lyon 1, Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lymphoma Immunobiology Team, Pierre Bénite, France. Electronic address: mael.heiblig@chu-lyon.fr.

Bhavisha Patel (B)

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Yvan Jamilloux (Y)

Hospices Civils de Lyon, Hôpital de la Croix Rousse, Service de médecine interne, Lyon, France.

Classifications MeSH